Capillary blood sampling to examine SARS-CoV-2 antibodies in diabetes
Research type
Research Study
Full title
Understanding the increased risk of SARS-CoV-2 infection in individuals with diabetes: Capillary Testing for COVID-19 Diabetes (CTC-19 Diabetes) Study.
IRAS ID
294780
Contact name
Kathleen Gillespie
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Since first reported in December 2019, the novel SARS-CoV-2 coronavirus has led to a global pandemic. It is increasingly clear that older individuals and those with pre-existing conditions including diabetes are at increased risk from the complications of diabetes. We previously validated a low volume test with almost 100% sensitivity and specificity to detect antibodies to SARS-CoV-2. We have shown that we can use remote collection of capillary samples successfully and identify who have been infected by SARS-CoV-2. We can also discriminate between those infected by SARS-CoV-2 and those who have received current vaccines. In this study we will invite individuals with diabetes and those who are diabetes free to provide small volume capillary blood samples by post as well as questionnaire data to allow us understand better why individuals with diabetes are at increased risk.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
21/SW/0017
Date of REC Opinion
16 Feb 2021
REC opinion
Further Information Favourable Opinion